Grants for Independent School Districts

This grant provides funding and resources to organizations seeking to establish or enhance recycling programs, focusing on waste diversion and recycling education.

The Rural and Municipal Utility Cybersecurity (RMUC) Program is offering a grant opportunity for electric cooperative, municipal, and small investor-owned utilities with limited cybersecurity resources. The Advanced Cybersecurity Technology (ACT) 1 Prize is a three-phase competition that challenges eligible utilities to identify risks and implement solutions to improve their overall cybersecurity posture. Utilities that progress through the competition will receive cash prizes and technical assistance to invest in staff training, governance processes, and cybersecurity tools and technologies. To apply, interested applicants should review the official rules for the complete application process and requirements. Eligible utilities can then create a HeroX account, accept the ACT 1 Prize Competitor Agreement, and choose whether to compete as a team. Application templates are available to aid in completing the application. Additionally, Phase 1 applicants must participate in two mandatory virtual webinars. The ACT 1 Prize offers a total prize pool of up to $8.96 million in cash and technical assistance across three phases: Commitment, Planning, and Implementation. Each phase concludes with a prize award. In the Commitment Phase, utilities prepare submission packages describing their resources, need for improving cybersecurity, and commitment to participating. In the Planning Phase, utilities work with technical assistance providers to assess systems, identify training needs, understand risks and solutions, and draft an implementation roadmap. Finally, in the Implementation Phase, utilities make progress towards completing their roadmap with the help of technical assistance providers. Administered by DOE's National Renewable Energy Laboratory (NREL) and managed by DOE's Office of Cybersecurity, Energy Security, and Emergency Response (CESER), the RMUC Program's ACT 1 Prize is part of a larger initiative to enhance the cybersecurity posture of electric utilities. The program will provide $250 million over five years to support critical investments, deliver technical assistance, and provide cybersecurity training to utility workers. This will result in a more secure and resilient energy grid. Interested parties can visit the RMUC Program webpage for more information and to sign up for updates.

The Tarrant Foundation awards between 50 – 70 competitive grants annually. Because we believe we can have the most impact by concentrating these funds in Vermont, applications are accepted only from Vermont organizations. Seniors: Comfort and Dignity in Aging We believe in ensuring that seniors’ most basic needs are met, and in community-based supports that promote wellbeing and fight the premature limitation of independence. Our focus includes: independent living, nutrition, and activity & enrichment.

The Energy CLASS (Champions Leading the Advancement of Sustainable Schools) Prize is a grant opportunity offered by the U.S. Department of Energy State and Community Energy Program Office (SCEP). The prize aims to support local education agencies in establishing and training energy managers to identify, plan, and implement efficiency and health upgrades in schools. With $80 million available, the grant will help schools across the country lower utility costs, improve indoor environmental quality, and reduce carbon emissions. The Energy CLASS Prize consists of two phases. In Phase 1, up to 25 selected LEAs will receive $100,000 in cash prizes to support participation in a 12-month training program. In Phase 2, participants will undergo 80-160 hours of online educational courses and receive one-on-one support and coaching related to building upgrades. At the end of Phase 2, participants can submit a progress report and a plan for future building upgrades for a chance to win a $50,000 bonus prize. To apply, LEAs need to submit a statement of need, letters of support, and demonstrate their commitment to making building energy upgrades. Interested applicants should review the official rules for complete application instructions. For updates or questions, applicants can subscribe on the HeroX platform or contact the Energy CLASS Prize team directly at energyclassprize@nrel.gov.

This grant provides financial support to Vermont-based nonprofits focused on youth development, economic independence for working adults, senior care, and community enhancement initiatives.

The Equitable and Affordable Solutions to Electrification (EAS-E) Home Electrification Prize offers up to $2.4 million in prizes for innovative solutions that advance the electrification retrofits of residential homes across all building types and geographies. The goal is to make electrification more affordable and accessible in existing U.S. homes, with a focus on equitable solutions for all homeowners, including those in low-income and under-resourced communities. The prize supports design solutions, tools, and technology innovations that enable the switch to electric products and reduce carbon emissions. Low-power electrification solutions are strongly encouraged. The competition consists of two phases: Phase 1 focuses on presenting proposed solutions and up to five winners receive a $5,000 cash prize and a $75,000 voucher to work with DOE national laboratories. Phase 2 involves finalizing teams, demonstrating functional prototype solutions, and up to three winners receive prizes, with a top prize of $1 million. The competition is open to individuals, private entities, nonfederal government entities, and academic institutions. For more information, refer to the official rules document.

The Tarrant Foundation awards between 50 – 70 competitive grants annually. Because we believe we can have the most impact by concentrating these funds in Vermont, applications are accepted only from Vermont organizations. Working-Age Adults: Employment and Financial Independence We support strategies that promote and facilitate the journey to economic independence, and that ultimately reduce reliance on public assistance. Our focus includes: job training/retention, financial literacy, homelessness prevention, and community-based addiction recovery.

This funding opportunity supports researchers and institutions conducting clinical trials and studies to improve stroke treatment, recovery, and prevention through collaboration within a national network.

This funding opportunity supports early stage researchers in pursuing innovative and high-risk scientific projects that significantly diverge from their previous work, without the need for preliminary data.

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Clinical Network Hub (HUB). The purpose of this Notice of Funding Opportunity (NOFO) is to continue support for the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit for clinical trials focusing on the prevention of and early intervention in type 1 diabetes (T1D). The main objective of the HUB is to increase the efficiency and productivity of the TrialNet network by providing coordination of communications and outreach and developing new tools and approaches to increase screening, recruitment and retention. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

The National Cancer Institute (NCI) intends to issue the U54 Specialized Programs of Research Excellence in Cancer Health Disparities and Minority Health (CHD-MH SPORE) notice of funding opportunity (NOFO). The program will support a network of multidisciplinary, multi-institutional U54 CHD-MH SPOREs, which are multi-project awards uniquely focused on health disparities and/or minority health translational research for improved prevention, early detection, diagnosis, and treatment of cancer in populations who are underserved. U54 CHD-MH SPOREs can investigate more than one cancer type in underserved populations, including groups of highly related cancers (e.g., gastrointestinal or head and neck). The research supported through this program must be translational and must stem from research on human biology, addressing the interplay of various determinants of health with the biology of the disease. U54 CHD-MH SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant, which may include a clinical trial. This Notice of Intent to Publish is being provided to allow sufficient time for applicants to develop strong applications. The NOFO is expected to be published in late winter 2024 with only one expected application due date in late September 2024.

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose to establish a national Open Measurement Coordinating Network for Non-Pharmacological Alzheimer's Disease (AD) and AD-related Dementias (ADRD) Primary Prevention Trials. The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. Brain health equity is the fair distribution of brain health determinants, outcomes, and resources within and between segments of the population, regardless of social standing. Measures and methods of interest will test outcomes and mechanisms of action in settings customized for individuals with different needs and linked to real-world function. Applications must explain how the platform will meet evolving community needs and partner with other NIA-funded programs. Applications must also describe activities that will achieve the following objectives: Develop an organizational and governance structure to support the administration, innovation, and dissemination functions of the Network. Propose activities to establish a framework that will facilitate the development of innovative strategies for standardization and use of methods and measures across NIA-supported projects and support activities for the discovery and development of innovative and novel measures and data. Disseminate Network resources and products to the broader AD/ADRD research community. Ensure that all measures and methods development and validation occurs in a racially, ethnically, geographically, and diagnostically diverse set of participants, including members of NIH-defined Health Disparity Populations. This also includes establishing the acceptability and feasibility of using the proposed instruments in both cognitively normal individuals and persons living with cognitive impairment (PLWCI), including subjective cognitive decline. NIA is particularly interested in proposals that advance equity for populations disproportionately impacted by AD/ADRD. For example, Black and Hispanic Americans have a higher prevalence of AD/ADRD compared to non-Hispanic White Americans. Resources, including measurement instruments, methods, algorithms, code, documentation, and normative data will enable other, future measures and methods development projects that support AD/ADRD primary prevention research needs. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in early 2024 with an expected application due date in Spring/Summer 2024. This NOFO will utilize the U24 activity code.

The National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for the TrialNet Coordinating Center (TNCC). The TrialNet network identifies people with type 1 diabetes (T1D) at stages before and after onset of clinical symptoms and enrolls them in trials and studies aimed at prevention of progression to clinical disease and preservation of insulin production. The TNCC participates in ongoing studies and intervention trials as well as the design and conduct of new studies and intervention trials. The TNCC will: (1) support a wide range of research projects in varying stages of development, implementation and completion, and (2) provide data and sample management, including standardized acquisition, quality control, dissemination and public accessibility. The TNCC will be responsible for network administration and operations, including the evaluation, selection, and funding (through subcontracts) of Clinical Centers and central support units (such as laboratories) necessary for the conduct of TrialNets clinical studies. The TNCC PD/PI will be a voting member of the TrialNet Executive and Steering Committees, contributing to network leadership. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the U01 activity code. Details of the planned NOFO are provided below.

To reduce the incidence of overweight, obesity, pre diabetes, and/or diabetes in Tennessee. A request for applications (RFA) is issued every three years. The next RFA is expected to be issued in January 2025. A letter of intent (LOI) is required for an invitation to apply. The Notice of Award is posted in late April or early May with a July 1 start date. Project Diabetes funds are distributed through a request for reimbursement process. Therefore, applicants must have the funds needed to implement the project upfront. Grantees are reimbursed monthly for their expenses. To be alerted to the posting of this RFA and other TDH grants, sign up on the funding opportunities website https://www.tn.gov/health/funding-opportunities.html.

This grant provides funding for early stage investigators to pursue innovative and high-risk research projects involving human participants, without the need for preliminary data.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports researchers conducting fully remote clinical trials to evaluate the effectiveness of complementary and integrative health interventions, utilizing mobile health technologies without any in-person contact.

HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance. The goal of this initiative is to support research aimed at (1) identification of targets and pathways by which transcriptional activity of HIV can be suppressed in HIV reservoirs including the CNS in people with SUD, and (2) application of emerging small molecule drug discovery approaches to identify novel compounds that can be utilized as pharmacological probes and as drugs to suppress HIV transcription in people with HIV-SUD comorbidity.

This funding opportunity supports researchers conducting feasibility trials of mind and body interventions for high-priority health conditions, aiming to gather essential data for future large-scale clinical studies.

This Notice of Funding Opportunity (NOFO) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD). This program is intended to support Early Stage and New Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences. Investigators from diverse backgrounds, including those from underrepresented groups (e.g., seeNOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply. Investigators from categories A-C are particularly encouraged to work with their institutions to apply. Preliminary data are not required for this NOFO. All applications require a letter of affirmation from the applicant institution documenting the Investigators eligibility. Applications that do not include this letter will be administratively withdrawn.